Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
- 23 May 2024
- journal article
- research article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 64 (6) , 632-642
Abstract
Background: Chronic migraine exerts substantial negative impacts on daily functioning. Efforts to manage impaired functioning may result in medication overuse, which contributes to the worsening profile and chronification of migraine. The Migraine Functional Impact Questionnaire (MFIQ) is a recently developed measure assessing the impact of migraine on physical, social, and emotional function. Objective: The objective of this analysis was to assess changes in MFIQ scores following initiation or modification of migraine preventive medication and determine if changes in function are associated with changes in other aspects of migraine burden, such as headache frequency, headache intensity, and symptoms of anxiety and depression. Methods: This is a secondary analysis of data from the Medication Overuse Treatment Strategy (MOTS) trial, a prospective pragmatic clinical trial that investigated two treatment strategies for those with chronic migraine and medication overuse. Data from both treatment arms were pooled and analyzed using a pre–post design. Prior to and 12 weeks following initiation or modification of migraine preventive medication, participants completed a series of questionnaires that captured migraine characteristics, medication use, migraine‐related physical impairment (MFIQ), anxiety (Generalized Anxiety Disorder‐7), and depression (Patient Health Questionnaire 9 [PHQ‐9]) symptoms. Changes from baseline in all measures were assessed using the paired t ‐test. Relationships between changes in MFIQ scores and other measures were assessed using linear regression. Multivariable modeling was performed to determine which additional variables contributed to the change in MFIQ beyond that already explained by an individual variable. Model terms were selected by using elastic net regularization. Only those participants who completed the baseline and 12‐week MFIQ were included in this analysis. Results: Of the 537 patients, 88.2% were female, and the average age was 45 years (standard deviation 13). The mean frequency of days with moderate‐to‐severe headache improved 39.2% from 13.5 per 30 days at baseline to 8.1 per 30 days at week 12. The mean MFIQ Usual Activities Global score improved by 15.0 points (on a 100‐point scale). All five domains (Usual Activities Global, Usual Activities, Social Function, Emotional Function, Physical Function) of the MFIQ improved by a mean of at least 13.0 points. Changes in PHQ‐9 score, followed by changes in headache frequency, had the strongest associations with change in all domains of the MFIQ. Conclusions: The negative impact of chronic migraine with medication overuse on physical, social, and emotional functioning substantially lessened following initiation or modification of migraine preventive medication. Improved functioning, as measured by the MFIQ, was most strongly associated with reductions in depression scores and headache frequency, highlighting the importance of recognizing and monitoring changes in depressive symptoms, in addition to headache frequency and functional impairment, when evaluating response to preventive medications.Keywords
Funding Information
- Patient-Centered Outcomes Research Institute (PCS‐1504‐30133)
This publication has 24 references indexed in Scilit:
- Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ)Headache: The Journal of Head and Face Pain, 2018
- Psychopathological comorbidities in medication‐overuse headache: a multicentre clinical studyEuropean Journal of Neurology, 2015
- Prevalence of chronic headache with and without medication overuse: Associations with socioeconomic position and physical and mental health statusPain, 2014
- Depression and risk of transformation of episodic to chronic migraineThe Journal of Headache and Pain, 2012
- A systematic review of the psychosocial difficulties relevant to patients with migraineThe Journal of Headache and Pain, 2012
- Disability and mood state in patients with episodic and chronic migraine associated to medication overuseNeurological Sciences, 2012
- Risk factors for medication-overuse headache: An 11-year follow-up study. The Nord-Trøndelag Health StudiesPain, 2012
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- Depression and anxiety disorders associated with headache frequency. The Nord‐Trøndelag Health StudyEuropean Journal of Neurology, 2003
- The PHQ-9Journal of General Internal Medicine, 2001